Escitalopram for persistent symptoms of generalized anxiety disorder after CBT: A pilot study

Journal of Nervous and Mental Disease

Volumn 198, Issue 6, 2010, Pages 458-461

  Schneier, Franklin R ^a,b   Belzer, Kenneth D ^a,b   Kishon, Ronit ^a   Amsel, Lawrence ^a,b   Simpson, Helen Blair ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Anxiety disorders; Cognitive behavioral therapy; Efficacy; SSRI; Treatment resistant

Indexed keywords

ESCITALOPRAM;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HUMAN; INSOMNIA; IRRITABILITY; MALE; NAUSEA; NERVOUSNESS; PILOT STUDY; QUALITY OF LIFE; RESTLESSNESS; SIDE EFFECT; TREATMENT RESPONSE; TREMOR;

ADOLESCENT; ADULT; AGED; ANXIETY DISORDERS; CITALOPRAM; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; QUESTIONNAIRES; SEROTONIN UPTAKE INHIBITORS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77953330867     PISSN: 00223018     EISSN: None     Source Type: Journal    
DOI: 10.1097/NMD.0b013e3181da4d77     Document Type: Article

References (25)

1. Bandelow B, Baldwin DS, Dolberg OT, Andersen HF, Stein DJ (2006) What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder and generalized anxiety disorder? J Clin Psychiatry. 67:1428-1434.
2. Borkovec TD, Newman MG, Pincus AL, Lytle R (2002) A component analysis of cognitive behavioral therapy for generalized anxiety disorder and the role of interpersonal problems. J Consult Clin Psychol. 70:288-298.
3. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C (2009) Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta analysis. Lancet. 373:746-758.
4. Cohen J (1988) Statistical Power Analysis of the Behavioral Sciences. Hillsdale (NJ): Lawrence Erlbaum Associates.
5. Endicott J, Nee J, Harrison W, Blumenthal R (1993) Quality of life enjoyment and satisfaction questionnaire: A new measure. Psychopharmacol Bull. 29:321-326.
6. Fava GA, Savron G, Grandi S, Rafanelli C (1997) Cognitive-behavioral management of drug resistant major depressive disorder. J Clin Psychiatry. 58:278-282.
7. Feeny NC, Zoellner LA, Mavissakalian MR, Roy-Byrne PP (2009) What would you choose? Sertraline or prolonged exposure in community and PTSD treatment seeking women. Depress Anxiety. 26:724-731.
8. First MB, Spitzer RL, Gibbon M, Williams JBW (1995) Structured Clinical Interview for DSM IV Axis I Disorders. New York: New York State Psychiatric Institute, Biometrics Research.
9. Goodman WK, Bose A, Wang Q (2005) Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord. 87:161-167. (Pubitemid 41039938)
10. Grant BF, Hasin DS, Stinson FS, Dawson DA, June Ruan W, Goldstein RB, Smith SM, Saha TD, Huang B (2005) Prevalence, correlates, co-morbidity and comparative disability of DSM-IV generalized anxiety disorder in the USA: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med. 35:1747-1759.
11. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. Washington, DC: Superintendent of Documents, US Government Printing Office, US Department of Health, Education and Welfare. Publication No. 76-338.
12. Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol. 32:50-55.
13. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry. 23:56-62.
14. Hidalgo RB, Tupler LA, Davidson JR (2007) An effect-size analysis of pharmacologic treatments for generalized anxiety disorder. J Psychopharmacol. 21: 864-872.
15. Hoffart A, Due-Madsen J, Lande B, Gude T, Bille H, Torgersen S (1993) Clomipramine in the treatment of agoraphobic inpatients resistant to behavioral therapy. J Clin Psychiatry. 54:481-487.
16. Hunot V, Churchill R, Silva de Lima M, Teixeira V (2007) Psychological therapies for generalised anxiety disorder. Cochrane Database Syst Rev. (1): CD001848.
17. Kampman M, Keijsers GP, Hoogduin CA, Hendriks GJ (2002) A randomized, double-blind, placebo-controlled study of the effects of adjunctive paroxetine in panic disorder patients unsuccessfully treated with cognitive-behavioral therapy alone. J Clin Psychiatry. 63:772-777.
18. Meyer TJ, Miller ML, Metzger RL, Borkovec TD (1990) Development and validation of the Penn State Worry Questionnaire. Behav Res Ther. 28:487-495.
19. Power KG, Simpson RJ, Swanson V, Wallace LA (1990) Controlled comparison of pharmacological and psychological treatment of generalized anxiety disorder in primary care. Br J Gen Pract. 40:289-294.
20. Pull CB (2007) Combined pharmacotherapy and cognitive-behavioural therapy for anxiety disorders. Curr Opin Psychiatry. 20:30-35.
21. Shear K, Belnap BH, Mazumdar S, Houck P, Rollman BL (2006) Generalized anxiety disorder severity scale (GADSS): A preliminary validation study. Depress Anxiety. 23:77-82.
22. Stewart JW, Mercier MA, Agosti V, Guardino M, Quitkin FM (1993) Imipramine is effective after unsuccessful cognitive therapy: Sequential use of cognitive therapy and imipramine in depressed outpatients. J Clin Psychopharmacol. 13:114-119.
23. Wittchen HU (2002) Generalized anxiety disorder: Prevalence, burden and cost to society. Depress Anxiety. 16:162-171.
24. Yonkers KA, Dyck IR, Warshaw M, Keller MB (2000) Factors predicting the clinical course of generalised anxiety disorder. Br J Psychiatry. 176:544-549.
25. Zinbarg RE, Craske MG, Barlow DH (2006) Mastery of Your Anxiety and Worry, Therapist Guide (2nd ed). Oxford (England): Oxford University.